THX TS01

Drug Profile

THX TS01

Alternative Names: THX RS01; THX-TS01

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Therapix Biosciences
  • Class Anti-inflammatories; Antiemetics; Appetite stimulants; Cannabinoids; Ethanolamines; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Palmitic acids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome

Most Recent Events

  • 08 May 2017 Therapix Biosciences and Hannover Medical School plan a phase II trial for Tourette Syndrome in Germany
  • 01 Feb 2017 Phase-III clinical trials in Gilles de la Tourette's syndrome in USA (unspecified route) (NCT03066193)
  • 23 Dec 2016 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top